Schnieders Capital Management LLC Purchases 342 Shares of Eli Lilly and Company (NYSE:LLY)

Schnieders Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,224 shares of the company’s stock after purchasing an additional 342 shares during the quarter. Schnieders Capital Management LLC’s holdings in Eli Lilly and Company were worth $3,628,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC increased its position in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares in the last quarter. Sapient Capital LLC bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the third quarter worth approximately $435,736,000. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Eli Lilly and Company by 24.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after purchasing an additional 645,473 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LLY. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a report on Wednesday, February 21st. Truist Financial reiterated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Barclays boosted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research note on Monday, April 15th. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY traded up $14.29 during trading on Tuesday, hitting $745.62. 2,041,595 shares of the company were exchanged, compared to its average volume of 3,051,032. Eli Lilly and Company has a 52-week low of $370.68 and a 52-week high of $800.78. The stock has a 50 day moving average of $763.89 and a 200 day moving average of $664.05. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The company has a market cap of $708.46 billion, a PE ratio of 128.56, a P/E/G ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.09 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.